CRISPR-Cas systems have revolutionized genetic engineering, offering a precise and efficient method for genome editing.  This technology leverages the bacterial adaptive immune system, employing guide RNA molecules to direct the Cas nuclease to specific DNA sequences.  Following target recognition, Cas9 induces a double-strand break, triggering cellular DNA repair mechanismsâ€”non-homologous end joining (NHEJ) leading to insertions or deletions, or homology-directed repair (HDR) enabling precise gene replacement or insertion.  CRISPR's versatility extends beyond gene disruption; base editing and prime editing variants allow for targeted nucleotide substitutions without double-strand breaks, minimizing off-target effects.  While highly promising for therapeutic applications, including gene therapy for inherited diseases and cancer immunotherapy, challenges remain.  Off-target cleavage, delivery limitations to specific tissues, and ethical considerations surrounding germline editing require ongoing investigation.  Future research focuses on enhancing specificity, exploring novel Cas enzymes, and developing sophisticated delivery systems to fully realize the therapeutic and research potential of CRISPR-Cas technology.